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A B S T R A C T
Purpose
To study the relation between the presence of axillary lymph node (LN) involvement and age in
breast cancer.
Patients and Methods
The breast cancer database of the University Hospitals Leuven contains complete data on 2,227
patients with early breast cancer consecutively treated between 2000 and 2005. A multivariate
piecewise logistic regression model was used to analyze LN involvement in relation to age at
diagnosis. A similar analysis was then performed on a large, independent, population-based
database from the Eindhoven Cancer Registry to investigate whether the effects of the Leuven
model could be replicated.
Results
We observed a piecewise effect of age. That is, women up to 70 years of age were less likely to
have positive LNs with increasing age (odds ratio per 10-year increase, 0.87). In contrast, older
women were more likely to have positive LNs with increasing age. However, for older women, the
effect of age interacted with tumor size (P  .0044), suggesting that increasing age is associated
with increased risk of LN involvement, mainly in small tumors. These findings were replicated in
the Eindhoven Cancer Registry database.
Conclusion
Axillary LN involvement varies with age at diagnosis; its probability decreases with increasing age
up to the age of approximately 70 years, but increases again thereafter. However, this increase is
mainly seen in smaller tumors and suggests a different behavior of small breast cancers in older
adult patients. We hypothesize that decreased immune defense mechanisms, related with aging,
may play a role in earlier invasion into LNs.
J Clin Oncol 27. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Breast cancer is the most frequently occurring tu-
mor in older women in Europe and North Ameri-
ca.1 Advancing age is associated with more favorable
tumor biology indicated by increased hormone sen-
sitivity, less HER-2/neu overexpression, lower grad-
ing, and lower proliferation indices.2-4 However, at
the time of diagnosis, older adult patients more of-
ten have an advanced-stage breast cancer and
larger tumors.1
There has been conflicting data on lymph node
involvement and aging; some studies showed de-
creased involvement in older adult patients,5-7
whereas others did not find an effect3,4,8 or showed
increased involvement with increasing age.1,9 Be-
cause of discordant results between previous studies,
we decided to perform a retrospective analysis as-
sessing the connection between age and lymph node




The breast cancer database from the University Hos-
pitals (UH) Leuven in Leuven, Belgium, contains data on
3,549 patients from the period between 2000 and 2005.
Patients for the present retrospective study were first se-
lected according to the following inclusion criteria: female
patients diagnosed with invasive breast cancer; patients
who had received primary surgery at the UH Leuven (thus
excluding patients who had neoadjuvant systemic therapy
and patients who never had therapy/surgery before for
breast cancer); patients whose pathology was performed in
the UH Leuven; patients with no metastases at diagnosis.
In total, 2,568 patients fulfilled these criteria.
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Variables Studied
The following variables were included for analysis: age at diagnosis,
maximal microscopic tumor size (largest diameter), worst tumor grade, axil-
lary lymph node status including number of positive lymph nodes, estrogen
receptor (ER) and progesterone receptor (PR) status, and HER-2/neu status.
Lymph node status was analyzed as a binary variable indicating whether
positive lymph nodes were detected (ie, lymph node involvement). Determi-
nation of tumor grading and ER, PR, and HER-2/neu status was done accord-
ing to established procedures, which are described in more detail elsewhere.10
There were missing values for tumor size (n  97; 3.8%), tumor grade
(n  16; 0.6%), receptor status (n  146; 5.7%), and axillary lymph node
status (n  82; 3.2%). The 2,227 patients (86.7%) with complete information
were used for statistical analysis. Of the 82 patients with missing lymph node
status, 48 patients did not receive an axillary lymph node dissection (pNx); for
the remaining 34 patients, information on axillary lymph node dissection
was missing.
Statistical Analysis of the Leuven Data
First, descriptive statistics were computed, and univariate relationships
between all aforementioned variables and lymph node involvement were
evaluated using logistic regression. Logistic regression results are presented as
odds ratios (OR) with 95% CIs, unless stated otherwise. Because a nonlinear
relationship between age and lymph node involvement was expected based on
existing literature, lymph node involvement was also regressed on age using
nonparametric logistic regression based on locally weighted scatterplot
smoothing (lowess).11 This allowed us to investigate the true functional form
of the relationship between age and lymph node status.
Thereafter, multivariate logistic regression was used to predict lymph
node involvement. The following variables were considered as predictors in
the multivariate model: age at diagnosis (years), tumor size (millimeters),
tumor grade (1, 2, or 3), and combined ER, PR, and HER-2/neu receptor status
(six categoric levels: ER-negative/PR-negative /HER-2–negative, ER-negative/
PR-negative/HER-2–positive, ER-positive/PR-negative/HER-2–negative,
ER-positive/PR-negative/HER-2–positive, ER-positive/PR-positive/HER-
2–negative, ER-positive/PR-positive/HER-2–positive). Details on model
and variable selection are provided in the Appendix (online only).
Replication of the Model Using the Eindhoven Cancer
Registry Database
The logistic regression model predicting lymph node involvement based
on the Leuven data seemed both robust and well-fitting (see Results). We
therefore investigated whether the estimated effects of age and tumor size
would be replicated on an independent tumor database from the Eindhoven
Cancer Registry (ECR), Eindhoven, the Netherlands. Since 1955, the ECR
records data on all patients newly diagnosed with cancer in the southern part of
the Netherlands (covering an area with 2.3 million inhabitants, 17 hospital
locations, and two large radiotherapy institutes; there are no university hospi-
tals in the area). The ECR routinely collects data on tumor characteristics such
as date of diagnosis, subsite, histology, stage (TNM clinical classification),
primary treatment, and patient characteristics (eg, sex and date of birth).
A subset of the full data set, containing 3,234 patients diagnosed with
invasive breast cancer in 2005 and 2006, was used for the analysis. These
patients fulfilled the inclusion criteria applied to the Leuven database. We
chose not to use data from the period before 2005 since variables were recorded
more systematically since the end of 2004. Data on lymph node involvement,
ER, PR, and HER-2 status, tumor grade, and tumor size was missing in 9.2%,
2.9%, 3.8%, 18.5%, 16.4%, and 12.5% of the patients, respectively. As a result,
complete information was available for only 2,155 patients (66.6%). Because
of the large amount of missing values, which increases the risk for biased
results, we imputed the missing values using multiple imputation (MI).13,14
MI imputes missing values multiple times to account for uncertainty in the
imputations. Each imputation of the missing values results in a complete ECR
data set. We chose to impute missing values five times, as this is usually
sufficient.12,13 We thus had five complete ECR data sets on which to perform
the statistical analysis. Following standard MI practice,12,13 all analyses were
performed on each complete ECR data set, and the results were combined to
obtain the final results. See Appendix (online only) for details on the imputa-
tion procedure.
RESULTS
The tumor characteristics of the patients from UH Leuven and ECR
are shown in Tables 1 and 2. Here, age was arbitrarily divided into four
groups: younger than 50 years, 50 to 69 years, 70 to 79 years, and 80
years or older.
Univariate Analysis
Age had a fairly weak relationship with lymph node involvement
(OR per 10-year increase 0.91; 95% CI, 0.85 to 0.98). However, the
univariate nonparametric logistic regression suggested a piecewise
effect of age on lymph node status (Fig 1A). Age clearly seems to be
negatively related to lymph node involvement for women up to ap-
proximately 70 years and positively related for women who are older
than 70 years at diagnosis. Tumor size (OR per cm increase 1.58; 95%
CI, 1.49 to 1.68), tumor grade (OR per grade increase 1.64; 95% CI,
1.44 to 1.87), and HER-2/neu receptor status (OR, 1.51; 95% CI, 1.16
to 1.96) had clear positive relationships with lymph node involve-
ment. ER (OR 1.09; 95% CI, 0.84 to 1.42) and PR receptor status (OR,
1.14; 95% CI, 0.93 to 1.40) were not clearly related to the outcome.
Multivariate Logistic Regression
The nonlinear relationship between age and lymph node involve-
ment was still present when adjusting for the other predictors. Once
again, age had a piecewise effect on lymph node involvement, with the
effect reversing at approximately the age of 70 years. This particular
cutoff is also frequently used in clinical studies to separate older adult
from younger patients and has been suggested as a cutoff for geriatric
assessment.14 Thus it was decided to use a piecewise logistic regression
model15 with a different effect of age for patients up to 70 years and
patients older than 70 years. It is important to emphasize that we did
not fit two separate models, but rather one single piecewise logistic
regression model where we modeled age as changing its effect on
lymph node involvement at 70 years.
Standard statistical variable selection criteria, such as Akaike’s
information criterion and Bayesian information criterion16 and like-
lihood ratio P values (see Appendix, online only, for details), suggested
that the optimal model was obtained when keeping all predictors in
the model. However, ER-positive/PR-positive/HER-2 –positive tu-
mors seemed more often spread to the lymph nodes than other tu-
mors. A likelihood ratio 2 test suggested that the model could indeed
be simplified by reducing the combined ER, PR, and HER-2/neu
receptor status to a binary variable indicating whether all three recep-
tor statuses were positive or not (triple positivity). Next, the necessity
of interaction terms was investigated (see Appendix, online only, for
details). Interactions involving age were investigated before and
after the breakpoint separately. One interaction term was included
in the final model: for women older than 70 years, the effect of age
seems to interact with tumor size (P  .0044). The final model is
presented in Table 2. Model fit was good, as assessed by the Hosmer-
Lemeshow goodness-of-fit test. See Appendix, online only, for the
model equation.
Up to 70 years of age, the odds of lymph node involvement
decreased by 13% for each 10-year increase in age (OR, 0.87; 95% CI,
Wildiers et al
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0.78 to 0.96) and increased by 60% for each centimeter increase in
tumor size (OR, 1.60; 95% CI, 1.50 to 1.70). After the age of 70 years,
increasing age increased the risk of lymph node involvement, as did
increasing tumor size. However, for older women, the effects of age
and tumor size were not independent because of the interaction term.
This interaction term can be explained from two different angles.
Focusing on the effect of age, the positive effect of age in older women
was most pronounced for small tumors. On the contrary, for very
Table 1. Tumor Characteristics and Lymph Node Involvement in Relation to Age
Parameter
Age Category (years)
 50 50-69 70-79  80 Total
University Hospitals Leuven, No. 636 1,189 310 92 2,227
Histology, %
Ductal 86.8 84.7 82.0 82.0 84.9
Lobular 12.0 14.5 15.4 18.0 14.0
Other 1.2 0.8 2.6 0 1.1
Median tumor size, mm 22 20 24.5 30 20
Tumor grading, %
1 9.7 18.2 10.6 7.6 14.3
2 41.2 47.3 49.7 50.0 46.0
3 49.1 34.5 39.7 42.4 39.7
ER, % 85.1 88.6 87.1 88.0 87.4
PR, % 79.4 76.8 74.2 73.9 77.1
HER-2, % 14.3 10.9 8.4 9.8 11.5
Lymph node involvement, % 40.5 35.4 32.2 43.2 37.0
No positive lymph nodes 59.5 64.6 64.8 56.8 62.8
1-3 positive lymph nodes 26.7 25.3 23.2 28.4 25.6
 4 positive lymph nodes 13.8 10.1 12.0 14.8 11.6
Eindhoven Cancer Registry, No. 831 1,535 508 360 3,234
Histology, %
Ductal 83.8 80.5 77.8 81.4 81.0
Lobular 8.3 10.9 14.8 11.1 10.9
Other 7.9 8.6 7.5 7.5 8.1
Median tumor size, mm 19 16 17 23 18
Tumor grading, %
1 21.3 30.3 25.7 28.7 27.1
2 39.8 45.0 52.8 48.2 45.2
3 38.9 24.7 21.5 23.2 27.7
ER, % 77.9 83.1 90.4 88.9 83.6
PR, % 71.7 68.5 76.1 76.1 71.3
HER-2, % 18.7 15.2 11.0 10.8 15.0
Lymph node involvement, % 48.2 38.2 36.5 44.6 41.2
No positive lymph nodes 51.8 61.8 63.5 55.4 58.8
1-3 positive lymph nodes 35.2 26.6 27.0 34.1 29.7
 4 positive lymph nodes 13.0 11.6 9.5 10.5 11.5
Abbreviations: ER, estrogen receptor; PR, progesterone receptor.
Table 2. Multivariate Logistic Regression Model for Lymph Node Involvement, With Piecewise Effect of Age and Interaction Between Age and Tumor Size for
Women Older Than 70 Years
Variable
Leuven University Hospital (n  2,227) Eindhoven Cancer Registry (n  3,234)
OR 95% CI P OR 95% CI P
Age, years (for women  70) 0.87 0.78 to 0.96 .0048 0.82 0.76 to 0.90  .0001
Age, years (for women older
than 70) 2.93 1.60 to 5.35 .0008 1.84 1.25 to 2.71 .0023
Size, mm 1.60 1.50 to 1.70  .0001 1.89 1.69 to 2.11  .0001
Grade 1.28 1.10 to 1.48 .0009 1.19 1.03 to 1.36 .0172
Triple positive 2.09 1.43 to 3.06 .0001 1.06 0.76 to 1.46 .7373
Age  size (for women older
than 70 years) 0.78 0.66 to 0.92 .0044 0.81 0.67 to 0.99 .0414
NOTE. Model development on data from University Hospitals Leuven; model replication on data from the Eindhoven Cancer Registry.
Abbreviation: OR, odds ratio.
Expressed per 10-year increase in age and/or per centimeter increase in size, as applicable.
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large tumors, the risk of lymph node involvement even decreased with
increasing age. Focusing on the effect of tumor size, the positive effect
of tumor size in older women attenuated when age at diagnosis in-
creased. This joint effect of age and tumor size for older women is
demonstrated in Figure 2A, which shows the predicted probability of
lymph node involvement as a function of age for three arbitrarily
chosen groups according to tumor size: patients with a tumor size up
to 20 mm (compatible with T1 according to TNM staging system),
patients with a tumor size between 21 and 35 mm, and patients with a
tumor size larger than 35 mm. Finally, tumor grade and triple positiv-
ity each had an independent and general positive effect on lymph node
involvement (Table 2).
Tumor characteristics and lymph node involvement in relation
to tumor size are shown in Table 3. Here, tumor size was arbitrarily
divided into the same three groups as previously mentioned:  20
mm, 21 to 35 mm, and more than 35 mm. In general, lymph node
involvement was much more frequent in larger tumors (22.0%,
40.9%, and 67.4%, respectively). When looking in more detail, this
tendency was stronger for younger than for older patients. Also, for
large tumors, nodal involvement decreased with increasing age at
diagnosis (eg, 53.3% for  80-year-old patients with a tumor larger
than 35 mm v 75.2% for patients  50 years of age). For smaller
tumors, a different picture was seen: nodal involvement was less fre-
quent in younger compared with older patients.
Replication of the Effects of Age and Tumor Size on
the ECR Database
The univariate effect of age on lymph node involvement using
nonparametric regression is shown in Figure 1B. In the ECR data, a
similar piecewise effect of age on lymph node involvement was ob-
served, but possibly with a slightly lower breakpoint. Then, a multi-
variate logistic regression model with the same predictors was fitted to
investigate whether the effects of age and tumor size could be repli-
cated on an independent breast cancer database. The piecewise effect
of age and the interaction between age and tumor size for older
women were replicated (Table 2 and Fig 2B), even though the inter-
action effect is slightly weaker compared with the Leuven model (see
Appendix, online only, for the model equation). Tumor characteris-
tics and lymph node involvement in relation to tumor size are shown
in Table 3.
DISCUSSION
This study investigated the relation between lymph node involvement
and age in a large database from a single center (UH Leuven). Univar-
iate analysis showed a slight decrease in lymph node involvement with
age when age was considered as having a linear effect throughout its
whole range. However, nonparametric analysis suggested a piecewise
effect of age with a breakpoint of approximately 70 years. In multivar-
iate logistic regression, modeling the effect of age as being piecewise
linear, higher age at diagnosis decreased the risk of lymph node in-
volvement up to the age of 70 years, but increased the risk after the age
of 70 years. The effect of age after 70 years, however, interacted with
tumor size. More specifically, from the point of view of age at diagno-
sis, the positive effect of age was most pronounced in small tumors.
For large tumors, increasing age even decreased the risk of lymph node
involvement. From the point of view of tumor size, the positive effect
of this predictor on lymph node involvement became weaker as age at
diagnosis increased.
These findings were replicated in an independent data set of
3,234 women registered with breast cancer in the ECR. This suc-
cessful replication is a major strength of this study. Together, these
results provide good evidence that there is a decrease in lymph
node involvement up to a certain age, with an increase thereafter
(mainly in small tumors). The effect of age on lymph node involve-
ment by age is nonlinear.
An explanation for this nonlinearity is not evident, and it is
possible that two or more influencing factors, acting in a different way,
are responsible for the effect. One explanation could be that breast
tumors are detected in a later stage in older adult patients. There is no
systematic breast cancer screening at ages older than 70 years in Bel-
gium. Moreover, older adult patients wait longer before consulting a
physician.17 Consistent with existing literature,3,9 we observed that
tumors were larger at diagnosis in older adults. Because there is a clear
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Fig 1. Relation between age and lymph node involvement based on univariate
nonparametric logistic regression: (A) University Hospital Leuven data (n  2,227)
and (B) Eindhoven Cancer Registry data (n  3234).
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node involvement, the risk of lymph node involvement would thus
increase in older adults. However, there was an interaction between
age and tumor size on lymph node involvement for older women,
suggesting that the effect of age on lymph node involvement is not
independent of tumor size. More specifically, the interaction sug-
gested that the positive effect of age for older women is most pro-
nounced in smaller tumors ( 20 mm), whereas for large tumors,
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Fig 2. Scatterplots between age and the model’s predicted probability of lymph node involvement. Separate plots are shown for (A) the University Hospital Leuven
data (n  2,227, left plots) and (B) Eindhoven Cancer Registry data (n  3,234, right plots), and for women with tumor size up to 20 mm (top plots), tumor size between
21 and 35 mm (middle plots), and tumor size greater than 35 mm (bottom plots).
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that the increased lymph node involvement in older adults is only
related to the presence of larger tumors. It seems that it is mainly
the smaller tumors in older adult patients that metastasize more
frequently to the lymph nodes than in younger postmenopausal
patients, whereas the larger tumors in older adult patients metas-
tasize less frequently. Or, differently stated, if breast tumors in
older adults have the capacity to metastasize to lymph nodes, this
occurs in an earlier stage/smaller tumors than in younger post-
menopausal patients.
One might consider selection bias as a cause of the age-related
effects. Axillary surgery is sometimes omitted in older adult pa-
tients with small tumors and a clinically node-negative axilla, be-
cause previous studies have not been able to show survival benefit
from axillary surgery in this population.18,19 This could lead to a
higher percentage of lymph node involvement in the older adult
population where an axillary dissection was performed. However,
an axillary dissection was not performed in only 48 patients be-
cause of several reasons (eg, small unexpected invasive foci, unfit
for general anesthesia), and 26 of these 48 patients were  70 years
of age. Selection bias, if present, was thus probably limited. This is
supported by the observation that the effects concerning age and
size were confirmed in an independent database where missing
values were imputed using multiple imputation.
In the Leuven data, the odds of lymph node involvement for
triple positive tumors (ER, PR, HER-2 positive) was 2.09 times higher
than for other tumors (95% CI, 1.43 to 3.06). In the ECR data,
however, the OR was only 1.06 (95% CI, 0.76 to 1.46), suggesting a
lack of effect. We do not have a full explanation for this difference, but
major differences in immunohistochemical techniques and cutoff val-
ues for positivity throughout the 17 different Dutch hospital settings
might have had serious impact on these results.
The piecewise effect for age required the specification of a
breakpoint. However, in reality, we are probably not dealing with a
breakpoint in the hard sense but rather with a transition phase that
was best modeled using a piecewise effect. A breakpoint of 70 years
was used in this study because the turning point was at approxi-
mately the age of 70 years in the multivariate analysis. Moreover, 70
years is a clinically relevant turning point.14 The biologic reason for
this breakpoint/transition phenomenon is not clear. Breast cancer
has a somewhat different biologic behavior in older adult patients
versus younger patients. Advancing age is associated with more
favorable tumor biology.2-4,6,20 On the other hand, there is a clear
Table 3. Tumor Characteristics and Lymph Node Involvement in Relation to Tumor Size and Age
Parameter
Tumor Size (mm)
 20 21-35  35
No. % No. % No. %
University Hospitals Leuven, No. 1,115 646 466
Median age, years 57 57 56
Tumor grade
1 22.0 9.1 3.2
2 48.2 40.3 48.7
3 29.9 50.6 48.1
ER 88.5 85.9 86.7
PR 78.1 75.1 77.3
HER-2 10.0 13.5 12.2
Lymph node involvement per age group
 50 years 296 22.0 195 45.6 145 75.2
50-69 years 654 21.3 317 39.4 218 67.4
70-79 years 134 22.4 103 33.0 73 57.5
80 years 31 35.5 31 51.6 30 53.3
Overall 22.0 40.9 67.4
Eindhoven Cancer Registry 1,936 1,014 284
Median age, years 59 58 62
Tumor grade
1 33.5 18.8 12.7
2 46.6 43.0 43.9
3 19.9 38.2 43.4
ER 87.6 79.1 72.3
PR 74.8 67.7 60.3
HER-2 13.0 17.9 17.5
Lymph node involvement per age
group, years
 50 460 38.3 291 54.9 80 80.9
50-69 1,015 27.4 432 55.7 88 77.4
70-79 315 24.7 145 50.9 48 71.1
80 146 31.9 146 50.5 68 59.5
Overall 29.9 54.0 73.0
Abbreviations: ER, estrogen receptor; PR, progesterone receptor.
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suppressed cellular immunity in older adults,21 and the most im-
portant determinant is age as such rather than age-associated dis-
eases.22 The number of tumor-infiltrating lymphocytes in breast
cancer decreases with age.23 Moreover, patients with breast cancer
with high cell-mediated immunity to tumor-associated antigens
have a better prognosis than those with low immunity, indicating
that immunologically unreactive patients are at risk for disease
recurrence.24 Thus altered or decreased immunologic function
could result in decreased defense against invasion and increased
nodal metastasizing, in a subset of breast tumors in older adults. In
the large Surveillance, Epidemiology, and End Results database,3
breast cancer survival in older women seemed to be similar to
survival in the general population irrespective of disease status. It
might well be that there is a balance in older adults between the less
aggressive biologic phenotype on the one hand and the decreased
immunologic defense on the other hand, resulting in status quo on
the level of breast cancer survival. Immunologic and microarray
studies might further help in elucidating age-related differences in
tumor behavior and immunology. This might ultimately lead to
better insight in tumor biology of breast cancer in general and
reveal new opportunities for directing anticancer strategies.
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Appendix
Details on the Methodology of the Multivariate Model on the Leuven Database
The multivariate analysis started with investigating the level of multicollinearity among the possible predictors. Next, for each predictor, we
checked the assumption of linearity in the logit conditional on the other possible predictors (Hosmer DW, Lemeshow S. Applied logistic
regression (ed 2). New York, NY, Wiley, 2000). Transformations, or other adjustments to predictors, were made if this assumption was violated.
For variable selection, we focused on the Akaike and Bayesian Information Criteria (AIC, BIC)16 and on the likelihood ratio P value and odds ratio
(OR) for each variable. The AIC and BIC are model selection statistics that penalize for the number of predictors used. The AIC has the tendency
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to select too many inputs, whereas the BIC has the tendency to select too few.16 Therefore, instead of leaning on just one of these criteria, we
monitored both, while simultaneously evaluating whether the resulting model seemed plausible from a clinical point of view.
Thereafter, the need to include interactions was investigated. However, caution on the inclusion of interactions is advised in statistical
literature (Hosmer DW, Lemeshow S. Applied logistic regression (ed 2). New York, NY, Wiley, 2000; Harrell FE, Lee KL, Mark DB. Stat Med
15:361-387, 1996). Because of the large sample size and the extra risk of overfitting for complex terms (such as interactions), we were prudent
concerning the inclusion of interaction terms. We investigated all two-way interactions one by one, as well as through stepwise and manual
selection procedures. The main criterion for evaluating interactions was the BIC, as this is a strict statistic for model selection. A second criterion
was the likelihood ratio P value for each interaction.
Finally, influence diagnostics were investigated to check for outliers and the extent to which they influence the model’s results. All statistical
tests were two-sided and were performed with SAS version 9.1 (SAS Institute Inc, Cary, NC).
Details on the Multiple Imputation Procedure for Missing Values in the Eindhoven Cancer Registry Data Set
We imputed the missing values in the Eindhoven Cancer Registry (ECR) data set five times. Each imputation was based on an iterative
algorithm along the lines of, but not identical to, Siddique and Belin (Stat Med 27:83-102, 2008). The variables considered were both core
variables and auxiliary variables. The core variables were the number of affected lymph nodes (0, one to three, four or more), age, size, estrogen
receptor, progesterone receptor, HER-2, and grade. The auxiliary variables were histology (ductal, lobular, mixed, other; no missing values),
TNM staging for tumor (1 to 4; 11.8% missing values), and inclusion year (2005 or 2006; no missing values). Auxiliary variables are used to
improve the quality of the imputations (Rubin DB. J Am Stat Assoc 91:473-489, 1996; Schafer JL. Analysis of incomplete multivariate data.
London, United Kingdom, Chapman and Hall, 1997). A completed data set was constructed as follows. In the first step, initial imputations for
missing values were obtained using the expectation-maximization algorithm, with the assumption that the joint distribution of all variables
involved is multivariate normal. In the second step, all variables with missing values were imputed in a predefined random order (this is the first
iteration). Each variable was imputed using the information from all remaining variables. If one of the remaining variables had missing values too,
the most recent imputations of these missing values were used such that all patients could be used. The continuous variable size was imputed using
predictive mean matching (PMM) regression (Schenker N, Taylor JMG. Comput Stat Data Anal 22:425-446, 1996); categoric or ordinal variables
were imputed using logistic regression. (A short description of how these methods work is given at the end of this appendix.) In the third
step, the second step was repeated a number of times (new iterations). We used 80 iterations to decrease the effect of the initial imputations
and variable imputation order on the final imputations. In addition, we observed that 80 iterations provided fairly stable results. We
repeated the whole procedure five times to produce five completed data sets. Typically, three to 10 completed data sets suffice for MI.12
The imputation model should be rich (hence the use of auxiliary variables) and should include any association that is the subject of
investigation in subsequent analyses (Schafer JL. Analysis of incomplete multivariate data. London, United Kingdom, Chapman and Hall, 1997).
In the Leuven data, we detected a piecewise effect of age on lymph node involvement, with the effect of age changing at approximately 70 years of
age (see Results). In addition, for women older than 70 years, the effect of age interacted with tumor size. Because we aimed to validate these effects
using the ECR data, we had to include these associations in the imputation model. Therefore, we performed the MI procedure separately for
women up to 70 years and women older than 70 years. Furthermore, for the latter group of patients, the PMM regression model to impute size
included the interaction effect of age and number of affected lymph nodes, and the logistic regression model to impute the number of affected
lymph nodes included the interaction effect of age and size.
The PMM regression method to impute size starts with fitting an ordinary least squares regression model. Then, new values for the model
parameters are drawn from their posterior distribution. Using these new values, a predicted value for size is constructed for each patient. For a
patient x with missing tumor size, we select the five patients with available tumor size whose predicted value for size is closest to that for x. One of
the five closest matches is selected at random, and its tumor size is used to impute the missing size of patient x.
Similarly, the logistic regression method to impute categoric/ordinal variables starts with fitting a logistic regression model. Then, new values
for the model parameters are drawn from their posterior distribution. The new values are used to compute the probability of each value of the
target variable. One specific value is randomly imputed using these probabilities. Both methods were implemented using PROC MI in SAS.
Combining the results of the five completed data sets was done using PROC MIANALYZE in SAS.
Multivariate Logistic Regression Model on the Leuven Database
The probability of lymph node involvement was estimated as 1/(1  ez), where
z  1.6616  0.01433  age  0.1217  (age  70)  age group  0.04677  size  0.002516  (age  70)
 age group  size  0.2443  grade  0.7386  triple positivity (TP) (1)
Age group equals 0 if the patient is up to 70 years and 1 if the patient is older than 70 years. This allowed the reformulation of the model for younger
and older patients separately, by replacing age group with 0 or 1, respectively:
zyoung  1.6616  0.01433  age  0.04677  size  0.2443  grade  0.7386  TP (2)
zold  10.1806  0.1074  age  0.2229  size  0.002516  age  size  0.2443  grade  0.7386  TP (3)
Multivariate Logistic Regression Model on the ECR
The probability of lymph node involvement was estimated as 1/(1ez), where:
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z  0.8877  0.01947  age  0.08058  (age  70)  age group  0.06342  size 0.002050  (age  70)
 age group  size  0.1706  grade  0.05518  TP (4)
Reformulating the model for younger and older patients separately gave:
zyoung  0.8877  0.01947  age  0.06342  size  0.1706  grade  0.05518  TP (5)
zold  6.5283  0.06111  age  0.2069  size 0.002050  age  size  0.1706  grade  0.05518  TP (6)
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